Table 3 |
|||
|
TNF-RII T676G single nucleotide polymorphism genotype frequencies and sTNFR levels |
|||
| Genotype |
n (%) |
sTNF-RI (pg/ml) |
sTNF-RII (pg/ml) |
|
|
|||
| Early RA |
|||
| TT |
63 (61.2) |
1,503 ± 704 |
4,690 ± 1,961 |
| TG |
33 (32.0) |
1,451 ± 370 |
3,961 ± 1,242 |
| GG |
7 (6.8) |
1,094 ± 240 |
3,648 ± 697 |
| Established RA |
|||
| TT |
91 (60.3) |
1,816 ± 705 |
5,837 ± 2,219 |
| TG |
51 (33.7) |
1,633 ± 642 |
5,375 ± 1,921 |
| GG |
9 (6.0) |
1,700 ± 570 |
5,187 ± 1,066 |
|
|
|||
|
Shown are tumour necrosis factor receptor II (TNF-RII) T676G single nucleotide polymorphism (SNP) genotype frequencies and soluble tumour necrosis factor receptor (sTNFR) levels in rheumatoid arthritis (RA) patients with early (n = 103) and established (n = 151) disease. sTNFR levels are expressed as the mean ± standard deviation. Multiple regression analyses of log transformed data corrected for age, sex and disease duration revealed a significant trend of decreasing soluble tumour necrosis factor receptor I (sTNF-RI) and sTNF-RII levels across the genotypes (order: TT > TG > GG) of patients with established disease (P for trend = 0.01 and P for trend = 0.03, respectively). A similar nonsignificant trend was seen for patients with early disease (P = 0.3 and P = 0.055, respectively). |
|||
|
Glossop et al. Arthritis Research & Therapy 2005 7:R1227 doi:10.1186/ar1816 |
|||
